Medicines Optimisation Innovation Centre

Name

Medicines Optimisation Innovation Centre

Legal name

Medicines Optimisation Innovation Centre

Website

https://themoic.hscni.net

Company type

Private

Founded year

2015

Operating status

Operating

Headcount range

1–10 employees

Ownership category

akta.pro rank

Product category

Medicines Optimisation Research and Innovation Services

NAICS

Scientific Research and Development Services (5417), Other Scientific and Technical Consulting Services (54169)

SIC

Services-Commercial Physical & Biological Research (8731), Services-Testing Laboratories (8734)

akta.pro primary industry

Global Health Research, Clinical Trials & Product Development Partnerships (PDPs) (HLAJAOAM)

akta.pro secondary industries

Clinical Quality Assurance (GCP QA, TMF/QMS oversight) (HLAGAKAI), Clinical Trials Authorization & Oversight (GCP) (HLAJADAF), Laboratory Quality Systems, Accreditation & Proficiency Testing Programs (HLAJAIAM)

Keywords

• Medicines optimisation
• Pharmacy services evaluation
• Polypharmacy management
• Pharmacist-led medication reviews
• Healthcare innovation research

Headquarters

HQ city

Antrim

HQ country

United Kingdom

HQ region

Europe

Offices1 record

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Operations, Technology or R&D, Marketing or Sales, Others

Revenue model

1. Government Commissioning: MOIC is commissioned by the Department of Health (DH) NI and works with SPPG to evaluate new services. As a regional centre under the Northern Health & Social Care Trust, MOIC operates within the public health system.
2. EU Grant Funding: MOIC participates in large-scale EU-funded projects including Horizon 2020 (SHAPES), INTERREG VA (iSIMPATHY, SIMPATHY), and PEACEPLUS (iMPROVE). Funding supports cross-border innovation programmes.
3. Innovation Voucher Services: MOIC delivers innovation voucher projects with Invest NI, providing knowledge sharing and expertise to SMEs through £5k innovation vouchers, supporting tailored innovation projects.

Go-to-market motion3 records

Distribution channels5 records

Marketing channels6 records

Core offering

MOIC is a publicly funded regional healthcare innovation centre that delivers medicines optimisation research, project management and professional expertise to the Northern Ireland health system and partners. It evaluates community pharmacy services, runs EU-funded cross-border innovation programmes (iSIMPATHY, SHAPES, iMPROVE), develops medicines management tools (EPICS, STEPSelect, LAMPs, Writemed), trains pharmacists in the 7-Steps methodology for polypharmacy reviews, and delivers SME innovation projects via Invest Northern Ireland knowledge vouchers.

Product overview

Medicines Optimisation Innovation Centre (MOIC) is a regional centre in Northern Ireland dedicated to delivering medicines optimisation. It is the only dedicated medicines optimisation centre in Europe. MOIC operates as a research and innovation organisation providing multiple products and services including clinical pharmacy tools (EPICS, STEPSelect, LAMPs, Writemed), pilot services (Cardiometabolic Pharmacy Service, Virtual Heart Failure Clinics), and participates in large-scale EU-funded projects (SHAPES, iSIMPATHY). The organisation also conducts evaluations of pharmacy services including Pharmacy First programmes and leads innovation projects such as AI-powered medication adherence systems.

Differentiator

Problem solved

Functional benefit

Products and services

• EPICS (Electronic Pharmaceutical Integrated Care System)
• STEPSelect
• LAMPs (Live Automated Microbiology Pharmacy surveillance)
• Writemed (Electronic Medication Reconciliation System)
• Cardiometabolic Pharmacy Service Pilot
• Virtual Heart Failure Clinics
• Novel System for Improving Medicines Adherence in Respiratory Diseases
• SHAPES (Smart and Healthy Ageing through People Engaging in Supportive Systems)
• iSIMPATHY (Implementing Stimulating Innovation in the Management of Polypharmacy and Adherence Through the Years)
• iMPROVE (Innovation in Person-Centred Medication Prescribing)
• Pharmacy First Sore Throat Pilot Service
• Pharmacy First Pilot Service for Treatment of Shingles
• Pharmacy First Service for Emergency Hormonal Contraception
• Stop Smoking Service in Community Pharmacy
• COMET (COVID-19 MEdicaTion) Study

Quantifiable outcome

• 6,481 person-centred medicines reviews delivered across NI, Scotland, and Ireland through iSIMPATHY
• +5 more outcomes

Named customers7 records

Segments4 records

Ideal customer profiles4 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature5 records

Partnerships

Twelve partnerships are on record, tiered core and minor.

• Ulster UniversitycoreStrategic or Co-development Partner · 4 February 2026MOIC signed a Memorandum of Understanding with Ulster University, marking a key step in deepening longstanding collaboration. The MOU unites MOIC's dedication to medicines optimisation with the university's expertise in Pharmacy & Pharmaceutical Sciences. Facilitated by the Centre for International Health Innovation and Partnerships and rooted in the School of Pharmacy & Pharmaceutical Sciences, this partnership strengthens translation of evidence into real-world medicines optimisation and better patient care.
• ATS Bergamo (Italy) - ProMIS ProgrammeminorStrategic or Co-development Partner · 4 December 2025MOIC hosted colleagues from ATS Bergamo through the ProMIS programme. The delegation studied Northern Ireland's best practices in drug review and deprescription in chronic patients, particularly the elderly with multiple diseases and frailty. The goal was to bring proven, innovative models back to Bergamo to make therapies safer, more appropriate, and sustainable.
• College of Health and Medical Sciences, Haramaya University (Ethiopia)coreStrategic or Co-development Partner · 25 November 2025MOIC signed a Memorandum of Understanding with the College of Health and Medical Sciences at Haramaya University, Ethiopia. Both parties committed to establishing open channels of communication to identify and pursue joint opportunities in medicines optimisation, including responding to funding calls, facilitating knowledge transfer, joint dissemination activities, and engaging key stakeholders. This partnership aligns with MOIC's key theme to build a culture of Partnership and Collaboration.
• Health Innovation Hub Ireland (HIHI)coreStrategic or Co-development Partner · 10 May 2025MOIC and Health Innovation Hub Ireland (HIHI) signed a Memorandum of Understanding at Stormont to build on existing relationships and allow for further collaboration to benefit the population's health across the island of Ireland. The MOU was signed in the presence of Health Minister Mike Nesbitt and Irish Minister of State Alan Dillon TD, formalising cross-border collaboration on innovation in healthcare and medicines optimisation.
• Association of the British Pharmaceutical Industry (ABPI)coreStrategic or Co-development Partner · 2 October 2024The Health and Social Care Industry Partnership (HSCIP) is a formal partnership agreement between ABPI and MOIC (acting on behalf of HSC NI). The partnership enables identification of areas of mutual interest to improve the diagnosis, treatment and care of patients. The shared goal is to deliver triple-win benefits: more rapid patient access to innovation, more effective use of HSC resources, and increased cross-sector research collaboration.
• Invest Northern IrelandcoreChannel Partner/ Reseller/ Distributor · 1 January 2020Since 2020, MOIC has been a Knowledge Provider for Invest NI. This role enables SMEs and potential entrepreneurs to collaborate with MOIC, accessing expertise and skills to drive innovation projects. Support is delivered through £5k innovation vouchers with the objective of boosting innovation among SMEs across Northern Ireland.
• Special European Union Programmes Body (SEUPB)coreStrategic or Co-development PartnerSEUPB managed the INTERREG VA Programme funding for iSIMPATHY (€3.5m, 3.5-year cross-border project). SEUPB is also a partner in the iMPROVE project (Peace Plus funding).
• iSIMPATHY Consortium Partners (Scotland, NI, Ireland)coreStrategic or Co-development PartneriSIMPATHY was a 3.5-year €3.5m project funded by the EU's INTERREG VA Programme, delivered in Scotland, Northern Ireland, and Republic of Ireland. The project trained pharmacists to deliver 6,481 person-centred medicines reviews using the 7-Steps methodology.
• SHAPES Consortium (36 partners across 14 European countries)coreStrategic or Co-development PartnerSHAPES was a large-scale EU-funded Horizon 2020 Innovation Action with 36 partners across 14 European countries, including healthcare providers, research organisations, technology companies, public authorities and end-user organisations. It aimed to build a European open ecosystem supporting healthy and independent living for older adults through digital solutions.
• Ghana Pharmacy DelegationminorStrategic or Co-development PartnerMOIC hosted a distinguished delegation from Ghana including Dr Paul Owusu Donkor, President of the Pharmaceutical Society of Ghana, and Dr Therestella Obosu Tei Kwabla, National Chairperson of the Community Practice Pharmacists Association of Ghana. The visit was part of a wider programme organised by Ulster University School of Pharmacy, focusing on pharmacy practice, medicines optimisation, and sustainability in healthcare.
• European Association of Hospital Pharmacists (EAHP)minorStrategic or Co-development PartnerProfessor Michael Scott MBE and Anita Hogg delivered two MOIC workshops on 'Exploring Clinical Pharmacy Services in Hospitals: Innovations and Challenges' at the 30th EAHP Congress in Barcelona, drawing strong interest from colleagues across Europe.
• Poland - Clinical Pharmacist Scaling ProjectminorStrategic or Co-development PartnerKamila Urbańczyk from Poland presented a project on scaling up a clinical pharmacist's service from pilot to national strategy in Poland, building directly on the iMM (innovative medicines management) work MOIC has been supporting. This demonstrates how the MOIC-developed IMM model continues to grow and spread internationally.

Scale indicators9 records

Recent moves6 records

Expansion highlights6 records

Others

• National Pharmacy Association (NPA): UK-wide trade association representing community pharmacy owners and delivering training, professional development and policy advocacy. Comparable to MOIC in supporting community pharmacy service development and medicines optimisation capability, but acts as membership body rather than innovation evaluator.

Broad incumbents

• Health Research Authority (HRA): UK regulator protecting and promoting the interests of patients and the public in health and social care research. Comparable in the clinical trials oversight and research governance space that MOIC operates in via INTERREG/Horizon projects, but a regulatory body rather than delivery partner.
• NIHR (National Institute for Health and Care Research): The UK's largest funder of health and care research, providing national infrastructure for clinical trials, applied research and innovation adoption. Comparable to MOIC in NHS-embedded research delivery but operates at vastly larger scale and broader remit.
• NHS Innovation Accelerator (NIA): England-based national programme scaling evidence-based innovations across the NHS, including medicines-related technologies. Comparable to MOIC's SME-collaboration and innovation-spread role but at pan-England scale and with broader innovation scope.

Direct peers

• Health Innovation Hub Ireland (HIHI): Ireland's national health innovation hub linking healthcare providers, academia and industry to commercialise innovative health solutions. Direct peer to MOIC: both are publicly funded national/regional health innovation intermediaries delivering pilots, evaluations and SME engagement, and they signed a formal cross-border MOU in 2025.
• InnoScot Health: Scotland's NHS-embedded health innovation body, formed to identify, develop and commercialise innovations from NHS Scotland staff. Direct peer to MOIC for cross-UK medicines and pharmacy innovation delivery, and was a partner on the iSIMPATHY consortium alongside MOIC.
• Health Innovation Manchester (HInM): Manchester-based NHS and academic health innovation centre driving adoption of proven innovations across Greater Manchester. Direct peer to MOIC as a UK regional health innovation accelerator delivering real-world evaluations and pathway redesign, although at significantly larger scale.
• Health Innovation Network (formerly AHSN Network, England): England's 15 Academic Health Science Networks, now unified as the Health Innovation Network, deliver NHS-embedded innovation spread, clinical evaluations and medicines optimisation programmes. Highly comparable model to MOIC at national scale, including polypharmacy and medicines safety workstreams.

Emerging players

• European Innovation Partnership on Active and Healthy Ageing (EIP on AHA): EU Commission partnership under which NI (with MOIC's contribution) achieved 4-star Reference Site status. Thematically and operationally comparable to MOIC's work on healthy ageing, polypharmacy and digital health pilots, but is a policy/coordination body rather than a service delivery centre.
• European Connected Health Alliance (ECHAlliance): International not-for-profit connecting health and social care ecosystems across Europe, including running the SHAPES ecosystem in which MOIC participated. Comparable as a cross-border digital health and ageing collaboration convener, but operates as a network rather than a centre delivering services.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks5 records

Key highlights6 records

Customer concentration

• Instagraminstagram.com/moic_hscni
• Xx.com/moicni
• LinkedInlinkedin.com/company/moic

Compliance1 record

Revenue estimate

Valuation estimate

Number of profiles

Profiles4 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Medicines Optimisation Innovation Centre